What is BiTE immunotherapy?
What is BiTE immunotherapy?
The BiTE® antibody construct represent an innovative immunotherapy approach that helps the body’s immune system target cancer cells and appears very promising for the treatment of lymphomas and multiple myeloma. BiTE is short for “bispecific T cell engager”. BiTEs are antibodies with two arms.
What is BiTE oncology?
BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients’ own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy.
How do BiTE antibodies work?
Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, BiTEs form a link between T cells and tumor cells. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules.
What is a bispecific drug?
Bispecific antibodies are artificial proteins that have promising applications in the field of cancer immunotherapy. They are comprised of two monoclonal antibodies held together by a flexible peptide linker. As the name suggests, this makes them able to bind to two different antigens.
What is tcell?
T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. Also called T lymphocyte and thymocyte. Enlarge. Blood cell development.
How do BiTE molecules work?
BiTE® molecules are deigned to form a bridge between cancer cells and cytotoxic T cells—white blood cells that can destroy other cells that pose a threat. One arm of the BiTE molecule binds to CD3, an antigen found on the surface of T cells. The other arm is engineered to bind to a tumor-associated antigen (TAA).
What is BiTE molecule?
BiTE® (Bispecific T cell Engager) molecules are a type of fusion protein that is designed to harness the power of the immune system to treat cancer. These bispecific molecules are created by linking the targeting regions of two antibodies.
What is a DuoBody?
The DuoBody® platform is a versatile platform technology for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.
What is a multispecific antibody?
Generally, multispecifics are chimeric proteins composed of IgGs. and smaller antibody fragments or multiple antibody fragments (Figure 1). Given their ability to bind. more than one target, multispecific antibodies have functional advantages for applications in which it is.
What is the T lymphocyte?
T lymphocytes are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. Also called T cell and thymocyte. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell.
What do T helper cells do?
Helper T cells are arguably the most important cells in adaptive immunity, as they are required for almost all adaptive immune responses. They not only help activate B cells to secrete antibodies and macrophages to destroy ingested microbes, but they also help activate cytotoxic T cells to kill infected target cells.
What is Fab arm exchange?
Human IgG4 is an unusually dynamic antibody, with half-molecule exchange (“Fab-arm exchange”) resulting in asymmetrical, bispecific antibodies with two different antigen binding sites, which contributes to its anti-inflammatory activity. The mechanism of this process is unknown.